芝加哥，2026 年 1 月 14 日（全球新闻通讯社）-- Cosmos Health Inc. （“Cosmos Health” 或 “公司”） （纳斯达克： COSM)，一家多元化的垂直整合全球医疗保健集团，今天宣布，Zacks 小型股研究（“Zacks”）已对公司启动覆盖，给予每股 4.50 美元的估值，相关研究报告于 2026 年 1 月 13 日发布，作者为分析师 Brad Sorensen。
Zacks 强调了 Cosmos Health 多元化的收入基础、垂直整合的制药和制造业务、技术驱动的举措、进入美国市场的扩展以及改善的财务表现，这些都是支持其估值的关键因素。
Zacks 小型股研究覆盖的主要亮点
以每股 4.50 美元的估值启动覆盖
Zacks 对 Cosmos Health 启动了覆盖，并基于折现现金流（DCF）分析给予了 每股 4.50 美元的估值，反映了预计的收入增长、改善的毛利率以及向正自由现金流过渡的模型。
估值方法
Zacks 采用了五年的折现现金流框架，使用 20% 的折现率，反映了公司的小型股特征和执行风险。该模型假设短期内收入适度增长，后期加速，自由现金流利润率稳步改善，以及 2% 的终端增长率。
强劲的收入增长前景
Zacks 预计 Cosmos Health 的收入将从 2025 年的约 6440 万美元增长到 2026 年的 9860 万美元，并在 2027 年进一步扩展到超过 1.3 亿美元，主要受益于高毛利的制药产品、品牌营养补充品和技术驱动的服务。
垂直整合的医疗保健平台
报告强调了 Cosmos Health 的垂直整合运营模式，涵盖制药分销、符合 GDP 标准的批发业务、GMP 认证的制造、专有营养补充品牌、远程医疗服务和人工智能驱动的研发。
进入美国市场
Zacks 提到 Cosmos Health 进入美国市场的扩展，特别是收购了 ZipDoctor，这是一家提供直接面向消费者的远程医疗订阅平台。报告还提到 Sky Premium Life 在美国营养补充市场的推出。
推进研发管线
Zacks 提到 Cosmos Health 的开发项目，包括用于肥胖和体重管理的 CCX0722，以及针对多发性硬化症、过敏和肿瘤相关适应症的其他再利用化合物，这些项目正在向临床和监管里程碑推进。这些研发努力反映了公司专注于识别和推进能够解决大疾病市场的候选药物。
通过 Cloudscreen 推动的人工智能创新
Zacks 指出收购 Cloudscreen，这是一种人工智能驱动的药物再利用和研发平台，作为支持 Cosmos Health 研发活动的关键技术。该平台利用计算机筛选和多模态生化数据来识别现有化合物的潜在新治疗用途，旨在缩短开发时间、降低发现成本，并支持潜在的许可或开发结果。
数字资产和区块链战略
报告指出，Cosmos Health 已实施数字资产配置计划，包括购买以太坊（ETH），并获得高达 3 亿美元的融资支持。Zacks 还提到公司与 Prime Ledger LLC 的战略合作伙伴关系，以管理数字资产并探索知识产权资产的代币化。
改善的财务表现和利润率扩展
Zacks 强调了 Cosmos Health 在 2025 年第三季度创下的记录，包括同比双位数的收入增长、显著提高的毛利润和改善的调整后 EBITDA，反映了运营执行和向高毛利活动的转变。
Cosmos Health 首席执行官 Greg Siokas 表示：“我们很高兴看到 Zacks 小型股研究对 Cosmos Health 启动覆盖，并认可我们在组织内执行的转型。这一覆盖强调了我们垂直整合模型的强大、我们加速的收入增长，以及我们在人工智能驱动的药物再利用、专有制药和营养补充品牌以及数字健康服务方面投资的战略重要性。随着我们继续扩大高毛利产品、推进我们的研发管线并改善运营效率，我们相信 Cosmos Health 正进入一个重要的拐点，为我们的股东创造可观的长期价值潜力。”
Cosmos Health 指出，它已向 Zacks 小型股研究支付了准备和发布该独立研究报告的费用，如报告中所披露。公司认为，向股东提供更广泛的第三方研究和分析的访问支持透明度和知情决策。
关于 Cosmos Health Inc. Cosmos Health Inc.（纳斯达克代码：COSM）成立于 2009 年，注册于内华达州，是一家多元化的垂直整合全球医疗保健集团。公司拥有一系列专有的制药和营养保健品牌，包括 Sky Premium Life®、Mediterranation®、bio-bebe®、C-Sept® 和 C-Scrub®。通过其子公司 Cana Laboratories S.A.，该公司在欧洲良好生产规范（GMP）下获得许可，并获得欧洲药品管理局（EMA）的认证，制造药品、食品补充剂、化妆品、生物杀灭剂和医疗设备。Cosmos Health 还通过其在希腊和英国的子公司向零售药房和批发分销商分销广泛的药品和非处方药，包括品牌仿制药和 OTC 药物。此外，公司已建立研发合作伙伴关系，针对肥胖、糖尿病和癌症等主要健康问题，利用人工智能药物再利用技术进行增强，并专注于新型专利营养保健品、专业根提取物、专有复合仿制药和创新 OTC 产品的研发。Cosmos Health 还通过收购总部位于美国德克萨斯州的 ZipDoctor, Inc. 进入了远程医疗领域。凭借全球分销平台，公司目前正在欧洲、亚洲和北美扩展，并在希腊的塞萨洛尼基和雅典以及英国的哈洛设有办事处和分销中心。更多信息请访问 www.cosmoshealthinc.com、www.skypremiumlife.com、www.cana.gr、www.zipdoctor.co、www.cloudscreen.gr，以及 LinkedIn 和 X。
前瞻性声明
除本新闻稿中包含的历史信息外，此处描述的事项可能包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明。诸如 “相信”、“期望”、“预期”、“打算”、“项目”、“估计”、“计划” 等词语，或 “将”、“应该”、“会”、“可能” 和 “能够” 等未来或条件动词，通常标识前瞻性声明，尽管并非所有前瞻性声明都包含这些词语。这些声明涉及风险和不确定性，可能因多种超出公司控制的原因单独或重大影响此处讨论的事项，包括但不限于：公司筹集足够资金以实施其商业计划的能力；其数字资产策略的有效性，包括积累和产生收益的活动；乌克兰战争对公司业务、运营和整体经济的影响；以及公司成功开发和商业化其专有产品和技术的能力。提醒读者不要对这些前瞻性声明过度依赖，因为实际结果可能与预期有重大差异。鼓励读者查看公司向 SEC 提交的风险因素，这些文件可在 SEC 网站（www.sec.gov）上获得。公司不承担更新或修订前瞻性声明的任何义务，无论是由于任何新信息、未来事件还是其他原因。
投资者关系联系方式：
BDG Communications
cosm@bdgcommunications.com
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UYzFPQ00zTXpZeE16WTJJekl5T1Rnd09UUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UYzFPQ00zTXpZeE16WTJJekl5T1Rnd09UUT0"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmZhZGU1MjAtN2RhMy00MjQyLTgzMWUtZDRmYmYzMGIxNjY5LTEzMDk2NDQtMjAyNi0wMS0xNC1lbg==/tiny/Cosmos-Health-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmZhZGU1MjAtN2RhMy00MjQyLTgzMWUtZDRmYmYzMGIxNjY5LTEzMDk2NDQtMjAyNi0wMS0xNC1lbg==/tiny/Cosmos-Health-Inc-.png"/>

COSM

Cosmos Health Inc.（纳斯达克代码：COSM）宣布，Zacks Small-Cap Research 已开始对其进行覆盖，给予每股 4.50 美元的估值。报告强调了公司多元化的收入、垂直整合以及向美国市场扩展等关键因素。Zacks 预计，2025 年的收入将从 6440 万美元增长至 2026 年的 9860 万美元，主要受高利润产品的推动。报告还提到研发方面的进展，包括基于人工智能的药物再利用和数字资产战略。首席执行官 Greg Siokas 强调了公司的转型及其为股东创造长期价值的潜力

CHICAGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (&#34;Cosmos Health&#34; or the “Company”) (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced that Zacks Small-Cap Research (“Zacks”) has initiated coverage on the Company with a valuation of $4.50 per share, according to a research report published on January 13, 2026 and authored by analyst Brad Sorensen.
<div class="lb-trans">芝加哥，2026 年 1 月 14 日（全球新闻通讯社）-- Cosmos Health Inc. （“Cosmos Health” 或 “公司”） （纳斯达克： COSM)，一家多元化的垂直整合全球医疗保健集团，今天宣布，Zacks 小型股研究（“Zacks”）已对公司启动覆盖，给予每股 4.50 美元的估值，相关研究报告于 2026 年 1 月 13 日发布，作者为分析师 Brad Sorensen。
</div>Zacks highlighted Cosmos Health’s diversified revenue base, vertically integrated pharmaceutical and manufacturing operations, technology-enabled initiatives, expansion into the U.S. market, and improving financial performance as key factors supporting its valuation.
<div class="lb-trans">Zacks 强调了 Cosmos Health 多元化的收入基础、垂直整合的制药和制造业务、技术驱动的举措、进入美国市场的扩展以及改善的财务表现，这些都是支持其估值的关键因素。
</div>Key Highlights from Zacks Small-Cap Research Coverage
<div class="lb-trans">Zacks 小型股研究覆盖的主要亮点
</div>Initiation of Coverage with $4.50 Per Share Valuation
<div class="lb-trans">以每股 4.50 美元的估值启动覆盖
</div>Zacks initiated coverage on Cosmos Health and assigned a $4.50 per share valuation based on a discounted cash flow (DCF) analysis, reflecting projected revenue growth, improving gross margins, and a modeled transition toward positive free cash flow over time.
<div class="lb-trans">Zacks 对 Cosmos Health 启动了覆盖，并基于折现现金流（DCF）分析给予了 每股 4.50 美元的估值，反映了预计的收入增长、改善的毛利率以及向正自由现金流过渡的模型。
</div>Valuation Methodology
<div class="lb-trans">估值方法
</div>Zacks applied a five-year discounted cash flow framework using a 20% discount rate, reflecting the Company’s small-cap profile and execution risk. The model assumes moderate near-term revenue growth, accelerating in later years, steady improvement in free cash flow margins, and a 2% terminal growth rate.
<div class="lb-trans">Zacks 采用了五年的折现现金流框架，使用 20% 的折现率，反映了公司的小型股特征和执行风险。该模型假设短期内收入适度增长，后期加速，自由现金流利润率稳步改善，以及 2% 的终端增长率。
</div>Strong Revenue Growth Outlook
<div class="lb-trans">强劲的收入增长前景
</div>Zacks projects Cosmos Health revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with further expansion to over $130 million by 2027, driven by higher-margin pharmaceutical products, branded nutraceuticals, and technology-enabled services.
<div class="lb-trans">Zacks 预计 Cosmos Health 的收入将从 2025 年的约 6440 万美元增长到 2026 年的 9860 万美元，并在 2027 年进一步扩展到超过 1.3 亿美元，主要受益于高毛利的制药产品、品牌营养补充品和技术驱动的服务。
</div>Vertically Integrated Healthcare Platform
<div class="lb-trans">垂直整合的医疗保健平台
</div>The report highlights Cosmos Health’s vertically integrated operating model, spanning pharmaceutical distribution, GDP-compliant wholesale operations, GMP-certified manufacturing, proprietary nutraceutical brands, telehealth services, and AI-enabled research and development.
<div class="lb-trans">报告强调了 Cosmos Health 的垂直整合运营模式，涵盖制药分销、符合 GDP 标准的批发业务、GMP 认证的制造、专有营养补充品牌、远程医疗服务和人工智能驱动的研发。
</div>U.S. Market Entry
<div class="lb-trans">进入美国市场
</div>Zacks references Cosmos Health’s expansion into the United States market, highlighted by the acquisition of ZipDoctor, a U.S.-based telehealth subscription platform providing direct-to-consumer access. The report also notes the launch of Sky Premium Life in the U.S. nutraceutical market.
<div class="lb-trans">Zacks 提到 Cosmos Health 进入美国市场的扩展，特别是收购了 ZipDoctor，这是一家提供直接面向消费者的远程医疗订阅平台。报告还提到 Sky Premium Life 在美国营养补充市场的推出。
</div>Advancing R&amp;D Pipeline
<div class="lb-trans">推进研发管线
</div>Zacks references Cosmos Health’s development programs, including CCX0722 for obesity and weight management, as well as additional repurposed compounds targeting multiple sclerosis, allergies, and oncology-related indications, with projects advancing toward clinical and regulatory milestones. These R&amp;D efforts reflect the Company’s focus on identifying and progressing candidates that address large disease markets.
<div class="lb-trans">Zacks 提到 Cosmos Health 的开发项目，包括用于肥胖和体重管理的 CCX0722，以及针对多发性硬化症、过敏和肿瘤相关适应症的其他再利用化合物，这些项目正在向临床和监管里程碑推进。这些研发努力反映了公司专注于识别和推进能够解决大疾病市场的候选药物。
</div>AI-Driven Innovation via Cloudscreen
<div class="lb-trans">通过 Cloudscreen 推动的人工智能创新
</div>Zacks identifies the acquisition of Cloudscreen, an AI-enabled drug repurposing and R&amp;D platform, as a key technology supporting Cosmos Health’s research and development activities. The platform uses in silico screening and multimodal biochemical data to identify potential new therapeutic uses for existing compounds, with the goal of shortening development timelines, reducing discovery costs, and supporting potential licensing or development outcomes.
<div class="lb-trans">Zacks 指出收购 Cloudscreen，这是一种人工智能驱动的药物再利用和研发平台，作为支持 Cosmos Health 研发活动的关键技术。该平台利用计算机筛选和多模态生化数据来识别现有化合物的潜在新治疗用途，旨在缩短开发时间、降低发现成本，并支持潜在的许可或开发结果。
</div>Digital Assets and Blockchain Strategy
<div class="lb-trans">数字资产和区块链战略
</div>The report notes that Cosmos Health has implemented a digital asset allocation program, including the purchase of Ethereum (ETH), supported by a disclosed financing facility of up to $300 million. Zacks also references the Company’s strategic partnership with Prime Ledger LLC to manage digital assets and explore tokenization of intellectual property assets.
<div class="lb-trans">报告指出，Cosmos Health 已实施数字资产配置计划，包括购买以太坊（ETH），并获得高达 3 亿美元的融资支持。Zacks 还提到公司与 Prime Ledger LLC 的战略合作伙伴关系，以管理数字资产并探索知识产权资产的代币化。
</div>Improving Financial Performance and Margin Expansion
<div class="lb-trans">改善的财务表现和利润率扩展
</div>Zacks highlights Cosmos Health’s record third quarter of 2025, which included double-digit year-over-year revenue growth, significantly higher gross profit, and improved adjusted EBITDA, reflecting operational execution and a shift toward higher-margin activities.
<div class="lb-trans">Zacks 强调了 Cosmos Health 在 2025 年第三季度创下的记录，包括同比双位数的收入增长、显著提高的毛利润和改善的调整后 EBITDA，反映了运营执行和向高毛利活动的转变。
</div>Greg Siokas, CEO of Cosmos Health, stated:“We are pleased to see Zacks Small-Cap Research initiate coverage of Cosmos Health and recognize the transformation we have been executing across our organization. This coverage underscores the strength of our vertically integrated model, our accelerating revenue growth, and the strategic importance of our investments in AI-driven drug repurposing, proprietary pharmaceutical and nutraceutical brands, and digital health services. As we continue to scale higher-margin products, advance our R&amp;D pipeline, and improve operational efficiency, we believe Cosmos Health is entering an important inflection point with substantial long-term value creation potential for our shareholders.”
<div class="lb-trans">Cosmos Health 首席执行官 Greg Siokas 表示：“我们很高兴看到 Zacks 小型股研究对 Cosmos Health 启动覆盖，并认可我们在组织内执行的转型。这一覆盖强调了我们垂直整合模型的强大、我们加速的收入增长，以及我们在人工智能驱动的药物再利用、专有制药和营养补充品牌以及数字健康服务方面投资的战略重要性。随着我们继续扩大高毛利产品、推进我们的研发管线并改善运营效率，我们相信 Cosmos Health 正进入一个重要的拐点，为我们的股东创造可观的长期价值潜力。”
</div>Cosmos Health notes that it has compensated Zacks Small-Cap Research for the preparation and publication of this independent research report, as disclosed in the report. The Company believes that providing shareholders with broader access to third-party research and analysis supports transparency and informed decision-making.
<div class="lb-trans">Cosmos Health 指出，它已向 Zacks 小型股研究支付了准备和发布该独立研究报告的费用，如报告中所披露。公司认为，向股东提供更广泛的第三方研究和分析的访问支持透明度和知情决策。
</div>About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
<div class="lb-trans">关于 Cosmos Health Inc. Cosmos Health Inc.（纳斯达克代码：COSM）成立于 2009 年，注册于内华达州，是一家多元化的垂直整合全球医疗保健集团。公司拥有一系列专有的制药和营养保健品牌，包括 Sky Premium Life®、Mediterranation®、bio-bebe®、C-Sept® 和 C-Scrub®。通过其子公司 Cana Laboratories S.A.，该公司在欧洲良好生产规范（GMP）下获得许可，并获得欧洲药品管理局（EMA）的认证，制造药品、食品补充剂、化妆品、生物杀灭剂和医疗设备。Cosmos Health 还通过其在希腊和英国的子公司向零售药房和批发分销商分销广泛的药品和非处方药，包括品牌仿制药和 OTC 药物。此外，公司已建立研发合作伙伴关系，针对肥胖、糖尿病和癌症等主要健康问题，利用人工智能药物再利用技术进行增强，并专注于新型专利营养保健品、专业根提取物、专有复合仿制药和创新 OTC 产品的研发。Cosmos Health 还通过收购总部位于美国德克萨斯州的 ZipDoctor, Inc. 进入了远程医疗领域。凭借全球分销平台，公司目前正在欧洲、亚洲和北美扩展，并在希腊的塞萨洛尼基和雅典以及英国的哈洛设有办事处和分销中心。更多信息请访问 www.cosmoshealthinc.com、www.skypremiumlife.com、www.cana.gr、www.zipdoctor.co、www.cloudscreen.gr，以及 LinkedIn 和 X。
</div>Forward-Looking Statements
<div class="lb-trans">前瞻性声明
</div>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
<div class="lb-trans">除本新闻稿中包含的历史信息外，此处描述的事项可能包含根据 1933 年证券法第 27A 条和 1934 年证券交易法第 21E 条的定义的前瞻性声明。诸如 “相信”、“期望”、“预期”、“打算”、“项目”、“估计”、“计划” 等词语，或 “将”、“应该”、“会”、“可能” 和 “能够” 等未来或条件动词，通常标识前瞻性声明，尽管并非所有前瞻性声明都包含这些词语。这些声明涉及风险和不确定性，可能因多种超出公司控制的原因单独或重大影响此处讨论的事项，包括但不限于：公司筹集足够资金以实施其商业计划的能力；其数字资产策略的有效性，包括积累和产生收益的活动；乌克兰战争对公司业务、运营和整体经济的影响；以及公司成功开发和商业化其专有产品和技术的能力。提醒读者不要对这些前瞻性声明过度依赖，因为实际结果可能与预期有重大差异。鼓励读者查看公司向 SEC 提交的风险因素，这些文件可在 SEC 网站（www.sec.gov）上获得。公司不承担更新或修订前瞻性声明的任何义务，无论是由于任何新信息、未来事件还是其他原因。
</div>Investor Relations Contact:
<div class="lb-trans">投资者关系联系方式：
</div>BDG Communications
<div class="lb-trans">BDG Communications
</div>cosm@bdgcommunications.com
<div class="lb-trans">cosm@bdgcommunications.com
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RZeU5UYzFPQ00zTXpZeE16WTJJekl5T1Rnd09UUT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTYyNTc1OCM3MzYxMzY2IzIyOTgwOTQ="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NmZhZGU1MjAtN2RhMy00MjQyLTgzMWUtZDRmYmYzMGIxNjY5LTEzMDk2NDQtMjAyNi0wMS0xNC1lbg==/tiny/Cosmos-Health-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NmZhZGU1MjAtN2RhMy00MjQyLTgzMWUtZDRmYmYzMGIxNjY5LTEzMDk2NDQtMjAyNi0wMS0xNC1lbg==/tiny/Cosmos-Health-Inc-.png"/>

Cosmos Health 宣布 Zacks Small-Cap Research 以 4.50 美元的估值开始分析师覆盖 | COSM 股票新闻